|Bid||0.1150 x 0|
|Ask||0.1500 x 0|
|Day's Range||0.1450 - 0.1450|
|52 Week Range||0.0800 - 0.9000|
|Beta (3Y Monthly)||-1.00|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Anyone researching Advanced Proteome Therapeutics Corporation (CVE:APC) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there are two main...
Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (APC.V) (0E8.F), is pleased to announce very positive results from animal studies in collaboration with Heidelberg Pharma. Antibody–drug conjugates (ADCs) are an emerging class of therapeutic agents with the potential to revolutionize current treatment strategies and regimens to fight cancer. The combination of APC's proprietary site-selective protein modification technology and Heidelberg Pharma's proprietary ATAC technology, featuring the mushroom toxin amanitin, has led to conjugates that possess high target-specific anti-cancer potency established in several human cancer cell types.